JPS6142558B2 - - Google Patents
Info
- Publication number
- JPS6142558B2 JPS6142558B2 JP54041203A JP4120379A JPS6142558B2 JP S6142558 B2 JPS6142558 B2 JP S6142558B2 JP 54041203 A JP54041203 A JP 54041203A JP 4120379 A JP4120379 A JP 4120379A JP S6142558 B2 JPS6142558 B2 JP S6142558B2
- Authority
- JP
- Japan
- Prior art keywords
- asparaginase
- molecular weight
- modified
- antigenicity
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 25
- 108010024976 Asparaginase Proteins 0.000 claims description 25
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical class [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 23
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000003827 glycol group Chemical group 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229960003272 asparaginase Drugs 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- UPLLQJUZZIYKHI-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;2-oxobutanedioic acid Chemical compound OC(=O)CC(=O)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O UPLLQJUZZIYKHI-DFWYDOINSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4120379A JPS55135590A (en) | 1979-04-05 | 1979-04-05 | Modified asparaginase and uricase and their preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4120379A JPS55135590A (en) | 1979-04-05 | 1979-04-05 | Modified asparaginase and uricase and their preparation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61093855A Division JPS6255079A (ja) | 1986-04-23 | 1986-04-23 | 修飾ウリカ−ゼ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55135590A JPS55135590A (en) | 1980-10-22 |
| JPS6142558B2 true JPS6142558B2 (show.php) | 1986-09-22 |
Family
ID=12601850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4120379A Granted JPS55135590A (en) | 1979-04-05 | 1979-04-05 | Modified asparaginase and uricase and their preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55135590A (show.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008105514A1 (ja) | 2007-02-28 | 2008-09-04 | Nof Corporation | 多分岐鎖ポリオキシアルキレン誘導体 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3126759A1 (de) * | 1981-07-07 | 1983-01-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung |
| JPS62175175A (ja) * | 1986-01-28 | 1987-07-31 | Mihama Hisaharu | 修飾トリプトフアナ−ゼ及びその製法 |
| HU226294B1 (en) * | 1998-08-06 | 2008-08-28 | Mountain View Pharmaceuticals | Peg-urate oxidase conjugates and use thereof |
| PT1588716E (pt) | 1998-08-06 | 2011-05-25 | Mountain View Pharmaceuticals | Conjugados de peg-urato oxidase e sua utiliza??o |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| HU229068B1 (hu) | 2005-04-11 | 2013-07-29 | Savient Pharmaceuticals | Urát oxidáz változatok és alkalmazásuk |
| JP5033177B2 (ja) | 2006-04-12 | 2012-09-26 | サビエント ファーマセウティカルズ インク． | 陽イオン界面活性剤によるタンパク質の精製 |
| SG10201408480RA (en) | 2009-06-25 | 2015-02-27 | Crealta Pharmaceuticals Llc | Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy |
| EP3538135A4 (en) | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
-
1979
- 1979-04-05 JP JP4120379A patent/JPS55135590A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008105514A1 (ja) | 2007-02-28 | 2008-09-04 | Nof Corporation | 多分岐鎖ポリオキシアルキレン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55135590A (en) | 1980-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2266041T3 (es) | Proteina serica y celular de anclaje y conjugados. | |
| Veronese et al. | Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly (ethylene glycol) | |
| JPS6142558B2 (show.php) | ||
| US4415553A (en) | Compositions, processes for their preparation and method for treatment of neoplasms | |
| IE63003B1 (en) | Macromolecular platinum antitumor compounds | |
| CN1211578A (zh) | 聚乙二醇－干扰素结合物 | |
| CN1255944A (zh) | 被修饰的精氨酸脱亚胺酶 | |
| CN102139114A (zh) | 聚合物-因子viii部分缀合物 | |
| EP0111388B1 (en) | Therapeutic compounds of platinum and palladium and their preparation | |
| WO2001055151A1 (en) | Polymeric micellar structure | |
| JPS6255079A (ja) | 修飾ウリカ−ゼ | |
| TW200540182A (en) | Altered fibronectin-binding protein of staphylococcus aureus | |
| CN101384276A (zh) | 口服胰岛素制剂制造方法 | |
| CN1045621C (zh) | 免疫球蛋白结合物的制备方法 | |
| JP2018530525A5 (show.php) | ||
| JPH05294994A (ja) | アクチノマイシンｄ複合体の製造方法 | |
| CN101591649B (zh) | 甲氧基聚乙二醇修饰的精氨酸脱亚氨酶及其制备与应用 | |
| EP1108738B1 (en) | Immunostimulating carrier for vaccines | |
| US3749774A (en) | Secretin preparation having prolonged action and the procedure of manufacture | |
| CA1247010A (en) | Fibronectin-dextran-drug complex and method of preparation thereof | |
| EP0374311A1 (en) | Urease antigen product | |
| JPS62175175A (ja) | 修飾トリプトフアナ−ゼ及びその製法 | |
| JPS58225025A (ja) | 効力持続性組成物 | |
| JPH03236400A (ja) | 化学修飾ポリペプチド及びその用途 | |
| JPS63264427A (ja) | 制癌作用物質複合体 |